IDEAYA Biosciences, Inc.
IDYANasdaq
$36.01
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↑ +62.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.2B
Enterprise Value
$2.5B
P/E
—
P/S
—
P/B
3.4
EV/EBITDA
—
PEG
—
FCF Yield
-2.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$140.1M
Free Cash Flow (TTM)
-$87.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-14.9%
ROIC
-54.5%
Debt / Equity
—
Net Cash
$671.2M
Return 1Y
+63.0%
Company profile
IDEAYA Biosciences, Inc. focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions.
- CEO
- Yujiro S. Hata
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- California
- Website
- ideayabio.com
Management & directors
- Ruiz Briseno AndresChief Accounting Officer
- Snyder Douglas B.SVP, General Counsel
Roles derived from SEC Form 4 filings.
Earnings
IDYA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.6M—
Diluted EPS-$1.11↑ +35.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$35.3M | -$50.3M | -$62.5M | -$134.4M | -$327.0M | -$159.3M |
| Net income | -$34.5M | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| Diluted EPS | -$1.40 | -$1.41 | -$1.42 | -$1.96 | -$3.36 | -$1.28 |
| Operating cash flow | $55.5M | -$55.8M | -$87.2M | -$115.2M | -$247.6M | -$71.1M |
| Free cash flow | $55.0M | -$58.4M | -$90.6M | -$117.6M | -$251.4M | -$73.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Net margin | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.0M | — | — | $207.8M | — | $6.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$64.9M | -$66.9M | -$144.1M | -$84.4M | -$88.8M | $108.5M | -$94.6M | -$108.5M |
| Net income | -$52.8M | -$51.8M | -$130.3M | -$72.2M | -$77.5M | $119.2M | -$83.3M | -$98.5M |
| Diluted EPS | -$0.68 | -$0.60 | -$1.55 | -$0.82 | -$0.88 | $1.33 | -$0.91 | -$1.11 |
| Operating cash flow | -$32.9M | -$49.2M | -$121.7M | -$60.3M | -$62.5M | $142.2M | -$90.5M | -$75.2M |
| Free cash flow | -$33.9M | -$49.7M | -$122.8M | -$61.7M | -$63.1M | $142.2M | -$90.8M | -$76.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -2059.1% | — | — | 52.2% | — | -1654.6% |
| Net margin | — | — | -1861.6% | — | — | 57.4% | — | -1502.1% |
Company news
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Ruiz Briseno Andres· Chief Accounting Officer | Sale | 9,550 | $40.01 | $382,130.84 | filing |
| 2026-07-07 | Ruiz Briseno Andres· Chief Accounting Officer | Option exercise | 9,550 | $12.86 | $122,813.00 | filing |
| 2026-03-02 | Stein Jeffrey | Buy | 50,000 | $32.96 | $1.6M | filing |
| 2025-11-28 | Ruiz Briseno Andres· See Remarks | Award | 1,253 | $16.91 | $21,183.84 | filing |
| 2025-11-28 | Snyder Douglas B.· SVP, General Counsel | Award | 1,041 | $16.91 | $17,599.67 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.